Výsledky vyhledávání - "Michael A. Fournel"

BIOETHICS FROM A PRAGMATIC PERSPECTIVE: ETHICAL ISSUES IN BIOPHARMACEUTICALS LA BIOÉTICA DESDE UNA PERSPECTIVA PRAGMÁTICA: TEMAS ÉTICOS EN LA INDUSTRIA BIOFARMACÉUTICA A BIOÉTICA A PARTIR DE UMA PESPECTIVA PRAGMÁTICA: TEMAS ÉTICOS NA INDUSTRIA BIOFARMACÊUTICA

Autor: Michael A Fournel

Publikováno v: Acta Bioethica, Vol 11, Iss 1, Pp 33-36 (2005)

In recent times competitive, commercial and fiscal pressures have introduced new and challenging issues for the pharmaceutical industry. This essay identifies some of these issues and proposes mechanisms for their resolution. This overview is not int

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::407153a5fb005dadd23dbeaca18d2ba7
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S1726-569X2005000100004

Zobrazit plný text záznamu

Clinical Safety, Tolerability, and Pharmacokinetics of Murine Monoclonal Antibody to Human Tumor Necrosis Factor

Autor: Christopher Spooner, James E. Pennington, Michael A. Fournel, Randy Allred, Janice C. Wherry, Norman Markowitz, Louis D. Saravolatz, Dan Remick

Publikováno v: Journal of Infectious Diseases. 169:214-217

The safety, tolerability, and pharmacokinetic profile of murine monoclonal antibody to human tumor necrosis factor-alpha (TNF alpha MAb) were evaluated in 20 uninfected patients at risk of sepsis and 16 septic patients. TNF alpha MAb was well tolerat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09a6211ed9f7572b8d562b386e2e782
https://doi.org/10.1093/infdis/169.1.214

Zobrazit plný text záznamu

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

Autor: Tongyao Liu, Glenn F. Pierce, Joanne Severs, Clark Pan, Hendri Tjandra, Jianmin Chen, John E. Murphy, Haiyan Jiang, Jonathan S. Strauss, Jim Newgren, Yaoqi Chen, Baisong Mei, Xin Zhang, Babu Subramanyam, Jian-Ming Gu, Michael A. Fournel

Publikováno v: Blood. 116(2)

A long-acting factor VIII (FVIII) as a replacement therapy for hemophilia A would significantly improve treatment options for patients with hemophilia A. To develop a FVIII with an extended circulating half-life, but without a reduction in activity,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01e5969526fdc7c2e7018e9ced52676d
https://pubmed.ncbi.nlm.nih.gov/20634383

Zobrazit plný text záznamu

LETHAL STAPHYLOCOCCUS AUREUS-INDUCED SHOCK IN PRIMATES

Autor: Dale J. Flournoy, Michael A. Fournel, Richard B. Passey, Alvin C. K. Chang, Fletcher B. Taylor, G. Peer, Cynthia K. Murray, Melinda Duerr, Stanley D. Kosanke, Lerner B. Hinshaw, Thomas E. Emerson, Gary L. White, Robert Xu

Publikováno v: The Journal of Trauma: Injury, Infection, and Critical Care. 33:568-573

A successful experimental treatment for gram-positive sepsis to our knowledge has not been achieved. The objectives of this study were to develop a nonhuman primate model of lethal gram-positive sepsis employing the micro-organism Staphytococcus aure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f18742a67dbd1a5dbeae02a7a835dff3
https://doi.org/10.1097/00005373-199210000-00013

Zobrazit plný text záznamu

A BIOÉTICA A PARTIR DE UMA PESPECTIVA PRAGMÁTICA: TEMAS ÉTICOS NA INDUSTRIA BIOFARMACÊUTICA

Autor: Michael A. Fournel

Publikováno v: Acta bioethica v.11 n.1 2005
SciELO Chile
CONICYT Chile
instacron:CONICYT
Acta bioethica, Volume: 11, Issue: 1, Pages: 33-36, Published: 2005

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca5b6ade3ca01288117975005b20de5
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S1726-569X2005000100004

Zobrazit plný text záznamu

Preclinical review of anti-tumor necrosis factor monoclonal antibodies

Autor: Michael A. Fournel, Lerner B. Hinshaw, Mark Bodmer

Publikováno v: Critical care medicine. 21

Objective To review the preclinical evidence for the role of tumor necrosis factor (TNF) in the pathogenesis of septic shock and to assess the preclinical efficacy of anti-TNF therapies for this clinical problem. Data sources The international Englis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ef0c45e9c2c0ed75ddf485af0c13a4
https://pubmed.ncbi.nlm.nih.gov/8403982

Zobrazit plný text záznamu

Towards a New Therapy for Hemophilia A: Evaluation of Multiple Approaches To Prolong the In Vivo Efficacy of Recombinant Factor VIII

Autor: Gary J. Jesmok, Clark Q. Pan, Baisong Mei, Mohan Parmathi, Hendri Tjandra, John E. Murphy, Michael A. Fournel, James Newgren, Klaus-Peter Radtke, Haiyan Jiang, Kyle Landskroner, Liang Tang, Joanne Severs, Pamela Esmon, Jonathan S. Strauss, John Teare

Publikováno v: Blood. 108:1606-1606

Prophylactic therapy with rFVIII has been shown to have a significant positive impact on the treatment of Hemophilia A. One of the impediments to effective prophylaxis is the requirement for frequent injections necessitated by the 12–14 hour circul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72ca19b6d170cbbc8837bd60271d6b2f
https://doi.org/10.1182/blood.v108.11.1606.1606

Zobrazit plný text záznamu

A Pharmacologic Evaluation of BAY 79-4980 (Liposome-Formulated Kogenate® FS) in the Hemophilia A Mouse

Autor: Glenn Pierce, Zhi-Hua Cui, Michael A. Fournel, Gary J. Jesmok, Deogracias Canivel, Kyle Landskroner

Publikováno v: Blood. 108:4003-4003

Background: BAY 79-4980 refers to recombinant FVIII (rFVIII; Kogenate®-FS, KGFS) reconstituted with a PEGylated Liposome diluent. rFVIII binds non-covalently but with high affinity on the external surface of the PEGylated Liposome and retains procoa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e521963317b5c5cf32c3fce4364d4dd5
https://doi.org/10.1182/blood.v108.11.4003.4003

Zobrazit plný text záznamu

Evaluation of PEG-FVIII Molecules with Prolonged Half-Lives in a Murine FVIII-Dependent Bleeding Model

Autor: Gary J. Jesmok, Zhi-Hua Cui, Kyle Landskroner, James Newgren, Glenn Pierce, Michael A. Fournel

Publikováno v: Blood. 108:1624-1624

Current treatment of patients with hemophilia A often requires the frequent infusion of Factor VIII (FVIII) due to its short circulating half-life. A longer-acting FVIII molecule could profoundly impact patients’ lives by extending bleeding protect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d06bc5b5069b273d27447b9297c976e5
https://doi.org/10.1182/blood.v108.11.1624.1624

Zobrazit plný text záznamu

In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency)

Autor: Alan R. Giles, Shawn Tinlin, Hugh Hoogendoorn, Nazreen Pancham, Paul K Ng, Michael A. Fournel

Publikováno v: Blood. 72:335-339

Infusion studies of recombinant factor VIII were performed in hemophilic (factor VIII-deficient) animals. Functional activity was determined using a standardized model of bleeding and kinetic characteristics charted by performing assays of factor VII

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f187251d1edcf16cda722425739c2b9
https://doi.org/10.1182/blood.v72.1.335.335

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání